Physician
Dardi, Loren
Dardi, Loren was paid $3.73M by Medicaid between Jan 2018 and Jul 2023, across 143 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 9.8% of everything it billed.
33Billing provider infoDARDI, LOREN
CHICAGO, IL 60625
CHICAGO, IL 60625
33aNPI1811091408assigned 09/12/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$3.73M
24GClaims761,045
24DCodes billed143
24AFirst – last monthJan 2018 – Jul 2023
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#18 of 398
Median peer was paid$66K
This provider vs. median57×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 94,448 | $396K | |
| 2019 | 151,709 | $621K | |
| 2020 | 197,716 | $896K | |
| 2021 | 149,878 | $772K | |
| 2022 | 100,379 | $650K | |
| 2023 | 66,915 | $395K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 9.8% | 71,433 | 48,121 | $365K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 9.3% | 119,465 | 77,888 | $348K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 6.8% | 3,868 | 3,281 | $255K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.9% | 22,669 | 20,386 | $182K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.8% | 43,523 | 28,994 | $181K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.5% | 4,356 | 3,774 | $130K |
| 84484 | 2.8% | 18,453 | 13,038 | $105K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.4% | 4,193 | 3,785 | $88K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.3% | 13,717 | 11,980 | $87K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.3% | 3,045 | 2,612 | $85K |
| 83874 | 2.3% | 9,177 | 7,299 | $85K | |
| 83735 | 2.2% | 24,490 | 9,417 | $83K |
131 more codes
| 87040 | 2.0% | 6,285 | $74K | |
| 82948 | 1.9% | 32,620 | $72K | |
| 80061 | Lipid panel | 1.9% | 22,836 | $69K |
| 82805 | 1.8% | 5,402 | $67K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 2,525 | $64K |
| 87088 | 1.5% | 10,237 | $56K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.5% | 17,633 | $55K |
| 87631 | 1.4% | 1,083 | $52K | |
| 83690 | 1.2% | 13,250 | $45K | |
| 83880 | 1.1% | 4,307 | $42K | |
| 84703 | 1.1% | 11,735 | $41K | |
| 81001 | 1.1% | 28,278 | $41K | |
| 83605 | 1.0% | 7,508 | $39K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,673 | $36K |
| 87400 | <1% | 5,559 | $35K | |
| 84439 | <1% | 7,900 | $34K | |
| 88307 | <1% | 511 | $33K | |
| 80306 | <1% | 5,487 | $32K | |
| 86850 | <1% | 10,822 | $31K | |
| 86901 | <1% | 13,824 | $31K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,373 | $30K |
| 84702 | <1% | 6,371 | $30K | |
| 84100 | <1% | 16,357 | $29K | |
| 85027 | <1% | 9,053 | $26K | |
| 86900 | <1% | 13,814 | $23K | |
| 83970 | <1% | 1,477 | $23K | |
| 82728 | <1% | 5,674 | $21K | |
| 82803 | <1% | 2,316 | $21K | |
| 87653 | <1% | 970 | $21K | |
| 84145 | <1% | 1,573 | $21K | |
| 85730 | <1% | 6,701 | $21K | |
| 85379 | <1% | 5,416 | $20K | |
| 85610 | <1% | 10,139 | $20K | |
| 87186 | <1% | 2,976 | $19K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 425 | $19K |
| 82570 | <1% | 7,653 | $18K | |
| 82607 | <1% | 2,926 | $17K | |
| 87081 | <1% | 5,907 | $17K | |
| 84466 | <1% | 3,972 | $17K | |
| 86803 | <1% | 1,997 | $16K | |
| 88342 | <1% | 1,122 | $15K | |
| 83540 | <1% | 4,639 | $15K | |
| 86328 | <1% | 319 | $14K | |
| 86140 | <1% | 5,485 | $13K | |
| 87340 | <1% | 1,983 | $12K | |
| 80074 | <1% | 651 | $12K | |
| 80202 | <1% | 1,604 | $11K | |
| 86756 | <1% | 1,245 | $10K | |
| 80076 | <1% | 3,214 | $10K | |
| 87486 | <1% | 427 | $10K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 427 | $9K |
| 82550 | <1% | 4,534 | $9K | |
| 82746 | <1% | 1,522 | $9K | |
| 82247 | <1% | 4,488 | $8K | |
| 84481 | <1% | 1,701 | $8K | |
| 83615 | <1% | 4,128 | $8K | |
| 87070 | <1% | 2,308 | $8K | |
| 88304 | <1% | 383 | $7K | |
| 87185 | <1% | 1,657 | $7K | |
| 85520 | <1% | 1,872 | $7K | |
| 84153 | <1% | 1,126 | $7K | |
| 82043 | <1% | 3,450 | $7K | |
| 84480 | <1% | 1,452 | $7K | |
| 85651 | <1% | 2,866 | $7K | |
| 87581 | <1% | 429 | $6K | |
| 86592 | <1% | 3,108 | $6K | |
| 81003 | <1% | 5,375 | $6K | |
| 87205 | <1% | 3,008 | $6K | |
| 83001 | <1% | 655 | $6K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 636 | $5K |
| 85018 | <1% | 4,299 | $5K | |
| 86706 | <1% | 689 | $5K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 362 | $5K |
| 84156 | <1% | 3,827 | $4K | |
| 85014 | <1% | 3,721 | $4K | |
| 82248 | <1% | 3,272 | $4K | |
| 84146 | <1% | 590 | $4K | |
| 86880 | <1% | 1,559 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 121 | $4K |
| 80055 | <1% | 192 | $3K | |
| 86431 | <1% | 754 | $3K | |
| 82565 | <1% | 1,124 | $3K | |
| 86762 | <1% | 640 | $3K | |
| 80069 | <1% | 597 | $3K | |
| 84550 | <1% | 1,392 | $3K | |
| 82950 | <1% | 1,093 | $2K | |
| 87493 | <1% | 106 | $2K | |
| 82436 | <1% | 1,024 | $2K | |
| 84300 | <1% | 1,113 | $2K | |
| 82784 | <1% | 183 | $2K | |
| 84133 | <1% | 1,025 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 91 | $2K |
| 84520 | <1% | 1,307 | $2K | |
| 81025 | <1% | 713 | $2K | |
| 82010 | <1% | 962 | $2K | |
| 83002 | <1% | 327 | $2K | |
| 80164 | <1% | 384 | $2K | |
| 85384 | <1% | 533 | $2K | |
| 84436 | <1% | 396 | $1K | |
| 85007 | <1% | 719 | $1K | |
| 87210 | <1% | 483 | $1K | |
| 86593 | <1% | 570 | $1K | |
| 88720 | <1% | 523 | $1K | |
| 82140 | <1% | 271 | $1K | |
| 85045 | <1% | 805 | $933.56 | |
| 83013 | <1% | 49 | $791.87 | |
| 82951 | <1% | 103 | $647.54 | |
| 88302 | <1% | 29 | $493.57 | |
| 88141 | <1% | 58 | $456.96 | |
| 86077 | <1% | 13 | $449.88 | |
| 82378 | <1% | 57 | $382.47 | |
| 88341 | <1% | 15 | $378.06 | |
| 88112 | <1% | 15 | $258.40 | |
| 83014 | <1% | 61 | $233.63 | |
| 83009 | <1% | 12 | $227.49 | |
| 82670 | <1% | 25 | $217.88 | |
| 82952 | <1% | 103 | $198.19 | |
| 82330 | <1% | 22 | $187.04 | |
| 87075 | <1% | 30 | $186.51 | |
| 82533 | <1% | 16 | $111.90 | |
| 86704 | <1% | 13 | $102.05 | |
| 80178 | <1% | 31 | $100.13 | |
| 87045 | <1% | 14 | $67.65 | |
| 83525 | <1% | 15 | $64.41 | |
| 84165 | <1% | 12 | $63.99 | |
| 82150 | <1% | 14 | $44.66 | |
| 83935 | <1% | 15 | $37.28 | |
| 87046 | <1% | 14 | $13.20 | |
| 86923 | <1% | 76 | $9.50 | |
| 87071 | 0% | 49 | $0.00 | |
| G0431 | Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter | 0% | 649 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.